All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-05-31T10:54:34.000Z

What unusual toxicities are seen in patients with ALL and what are the best strategies to manage them?

By Quintina Dawson
Featured
André Baruchel
Anita Rijneveld
Charles Mullighan
José María Ribera
Kjeld Schmiegelow
Oliver Ottmann
May 31, 2023
Share:
Learning objective: After reading this article, learners will be able to cite new clinical developments in ALL.

Bookmark this article

During the ALL Hub Steering Committee meeting, members discussed ongoing research to address unmet needs in the assessment and management of unusual and severe toxicities, in in both pediatric and adult acute lymphoblastic leukemia. This discussion was chaired by Kjeld Schmiegelow and featured Helene Hallböök, José María Ribera, Anita Rijneveld, André Baruchel, Oliver Ottmann, and Charles Mullighan.

What unusual toxicities are seen in patients with ALL and what are the best strategies to manage them?

The key unmet needs identified include global uniformity in the definition and management of unusual toxicities, evaluation of the long-term effects in patients experiencing toxicities, and re-exposure to novel therapies following toxicities.

More about...
Risk

Related articles

Add bookmark

What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?

During the recent ALL Hub Steering Committee meeting, members discussed strategies to optimize CAR T-cell therapy outcomes in pediatric, adolescents, and...

Dec 21, 2023
Add bookmark

What are the strategies to optimize outcomes in pediatric/AYA patients receiving CAR T-cells?

During the recent ALL Hub Steering Committee meeting, members discussed strategies to optimize CAR T-cell...

Dec 21, 2023
Add bookmark

How I sequence treatment for R/R B-ALL

During the last steering committee meeting (SC), held on May 19, 2022, the SC members discussed sequencing treatment in R/R B-ALL. The session was chaired by Hervé Dombret and included Wendy Stock, André...

Jul 28, 2022
Add bookmark

How I sequence treatment for R/R B-ALL

During the last steering committee meeting (SC), held on May 19, 2022, the SC members discussed sequencing treatment in R/R B-ALL. The session was chaired by...

Jul 28, 2022

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox